Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

202.47 -0.61 (-0.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
From Seagen Inc.
Via Business Wire
Looking Into Seattle Genetics's Return On Capital Employed
According to Benzinga Pro data, during Q1, Seattle Genetics (NASDAQ:SGEN) posted sales of $426.46 million. Earnings were up 21.84%, but Seattle Genetics still reported an overall loss of $136.49... 
Via Benzinga
4 Healthcare Funds With "Double Discounts"
There's nothing that closed-end fund investors love more than finding a smartly run fund in an unfairly beaten-down sector. This hands us a nice discount plus a much bigger dividend. Let's take a look... 
Via Talk Markets
Expert Ratings for Seagen
Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings: 
Via Benzinga
Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales
Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance. 
Via Benzinga
Recap: Seagen Q1 Earnings
Seagen (NASDAQ:SGEN) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Seagen beat estimated earnings by... 
Via Benzinga
Seagen Reports First Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
From Seagen Inc.
Via Business Wire
Earnings Scheduled For April 28, 2022
Companies Reporting Before The Bell • PBF Energy (NYSE:PBF) is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion. 
Via Benzinga
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
The  
Via Benzinga
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case
A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ: SGEN)  
Via Benzinga
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
From Seagen Inc.
Via Business Wire
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
From Seagen Inc.
Via Business Wire
Good Entry Point for Biotech Stocks
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms. 
Via Talk Markets
Top Nasdaq 100 Stocks: Trading Opportunities For Next Week
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some Nasdaq 100 stock opportunities by... 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets
 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
From Seagen Inc.
Via Business Wire
Tough Slogging Ahead for Investors, Diversification is Important
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Seagen Inc.
Via Business Wire
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Genmab A/S
Via Business Wire
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (... 
Via Benzinga
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
From Seagen Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.6% to $1.35 during Friday's regular session. As of 12:30 EST, Dermata Therapeutics's stock is... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.